If you have been reading about fatty diacid chain and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
==== Mongolia ==== After serious opposition about plans and negotiations between Mongolia with Japan and the United States to build nuclear-waste facilities in Mongolia, Mongolia stopped all negotiations in September 2011. These negotiations had started after U.S. Deputy Secretary of Energy Daniel Poneman visited Mongolia in September 2010. Talks took place in Washington, D.C. between officials of Japan, the United States, and Mongolia in February 2011. After this the United Arab Emirates (UAE), which wanted to buy nuclear fuel from Mongolia, joined in the negotiations. The talks were kept secret and, although the Mainichi Daily News reported on them in May, Mongolia officially denied the existence of these negotiations. Alarmed by this news, Mongolian citizens protested against the plans and demanded the government withdraw the plans and disclose information. The Mongolian President Tsakhiagiin Elbegdorj issued a presidential order on September 13 banning all negotiations with foreign governments or international organizations on nuclear-waste storage plans in Mongolia. The Mongolian government has accused the newspaper of distributing false claims around the world. After the presidential order, the Mongolian president fired the individual who was supposedly involved in these conversations.
== External links == Clinical trial number NCT05869903 for "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)" at ClinicalTrials.gov Clinical trial number NCT05872620 for "A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)" at ClinicalTrials.gov
The biosynthetic pathway of nicotine involves a coupling reaction between the two cyclic structures that comprise nicotine. Metabolic studies show that the pyridine ring of nicotine is derived from nicotinic acid, while the pyrrolidine is derived from N-methyl-Δ1-pyrrollidium cation. Biosynthesis of the two component structures proceeds via two independent syntheses, the NAD pathway for nicotinic acid and the tropane pathway for N-methyl-Δ1-pyrrollidium cation. The NAD pathway in the genus Nicotiana begins with the oxidation of aspartic acid into α-amino succinate by aspartate oxidase (AO). This is followed by a condensation with glyceraldehyde-3-phosphate and a cyclization catalyzed by quinolinate synthase (QS) to give quinolinic acid. Quinolinic acid then reacts with phosphoribosyl pyrophosphate catalyzed by quinolinic acid phosphoribosyl transferase (QPT) to form nicotinic acid mononucleotide (NaMN). The reaction now proceeds via the NAD salvage cycle to produce nicotinic acid via the conversion of nicotinamide by the enzyme nicotinamidase. The N-methyl-Δ1-pyrrollidium cation used in the synthesis of nicotine is an intermediate in the synthesis of tropane-derived alkaloids. Biosynthesis begins with decarboxylation of ornithine by ornithine decarboxylase (ODC) to produce putrescine. Putrescine is then converted into N-methyl putrescine via methylation by SAM catalyzed by putrescine N-methyltransferase (PMT).
== Operations == KCI is composed of three business units: Active Healing Solutions, LifeCell and Therapeutic Support Systems, that operate in the wound care, regenerative medicine and therapeutic support systems markets. The largest of these business units is dedicated to wound care primarily negative pressure wound therapy for the treatment of traumatic wounds, pressure ulcers, chronic wounds and diabetic ulcers but also assistance with surgery. The therapeutic support systems developed and supplied by KCI are largely for the treatment and prevention of complications associated with patient immobility. These include support surfaces for hospital beds and home patients designed to address pulmonary complications in immobile patients. KCI also develops specialty beds for use in hospitals or in long-term care facilities. KCI expanded into the regenerative medicine market in 2008. Through subsidiary company LifeCell Corporation, KCI develops and supplies tissue-based products. These include tissue-based treatments used in surgical procedures to repair soft-tissue.
Senescence-associated secretory phenotype (SASP) is a phenotype associated with senescent cells wherein those cells secrete high levels of inflammatory cytokines, immune modulators, growth factors, and proteases. SASP may also consist of exosomes and ectosomes containing enzymes, microRNA, DNA fragments, chemokines, and other bioactive factors. Soluble urokinase plasminogen activator surface receptor is part of SASP, and has been used to identify senescent cells for senolytic therapy. Initially, SASP is immunosuppressive (characterized by TGF-β1 and TGF-β3) and profibrotic, but progresses to become proinflammatory (characterized by IL-1β, IL-6 and IL-8) and fibrolytic. SASP is the primary cause of the detrimental effects of senescent cells. SASP is heterogenous, with the exact composition dependent upon the senescent-cell inducer and the cell type. Interleukin 12 (IL-12) and Interleukin 10 (IL-10) are increased more than 200-fold in replicative senescence in contrast to stress-induced senescence or proteosome-inhibited senescence where the increases are about 30-fold or less. Tumor necrosis factor (TNF) is increased 32-fold in stress-induced senescence, 8-fold in replicative senescence, and only slightly in proteosome-inhibited senescence. Interleukin 6 (IL-6) and interleukin 8 (IL-8) are the most conserved and robust features of SASP. But some SASP components are anti-inflammatory. Senescence and SASP can also occur in post-mitotic cells, notably neurons.
Sources: en.wikipedia.org
Members of the National Union of Journalists working for the BBC regional service in England vote to take strike action over planned cuts to BBC Local Radio. A 24-hour strike is scheduled for 15 March to coincide with Budget Day.
Determining which amino acid forms the N-terminus of a peptide chain is useful for two reasons: to aid the ordering of individual peptide fragments' sequences into a whole chain, and because the first round of Edman degradation is often contaminated by impurities and therefore does not give an accurate determination of the N-terminal amino acid. A generalised method for N-terminal amino acid analysis follows:
== B == bacillary band – bacteria – bacteriochlorin – bark – Barr body – basal body – basal metabolic rate – base – base pair – basement membrane – basidiomycetes – basidium – B cell – benthic zone – beta sheet – binary fission – binding site – bioassay – biodiversity – bioenergetics – biogeochemical cycle – biological magnification – bioluminescence – biome – biopolymer – biosphere – blood – blood–brain barrier – blotting – bond energy – book lung – botany – bottleneck effect – Bowman capsule – brain stem – bronchiole – Brønsted acid – Brønsted base – Brownian movement – bryophyte – bubonic plague – budding – bulk flow
dextroamphetamine (Dexedrine) dextroamphetamine (75%)/ levoamphetamine (25%) (Adderall) dextromethamphetamine (Desoxyn) Research has been done on the interaction between amphetamines and CYP2D6 enzyme, and researchers concluded that some parts of substrate molecules contribute to the binding of the enzyme.
== External links == FABP4+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human FABP4 genome location and FABP4 gene details page in the UCSC Genome Browser. PDBe-KB provides an overview of all the structure information available in the PDB for Human Fatty acid-binding protein, adipocyte PDBe-KB provides an overview of all the structure information available in the PDB for Mouse Fatty acid-binding protein, adipocyte
Sources: en.wikipedia.org
== Advantages == A major advantage of the SELDI process is the chromatographic separation step. While liquid chromatography-mass spectrometry (LC-MS) is based on the elution of analytes in the separated sample, separation in SELDI is based on retention. Any sample components that interfere with analytical measurements, such as salts, detergents, and buffers, are washed away before analysis with mass spectrometry. Only the analytes that are bound to the surface are analyzed, reducing the overall complexity of the sample. As a result, there is an increased probability of detecting analytes that are present in lower concentrations. Because of the initial separation step, protein profiles can be obtained from samples of as few as 25-50 cells. In biological applications, SELDI-TOF-MS has a major advantage in that the technique does not require the use of radioactive isotopes. Furthermore, an assay can be sampled at multiple time points during an experiment. Additionally, in proteomics, the biomarker discovery, identification, and validation steps can all be done on the SELDI surface.
Cyanosulfidic scenarios are mechanisms for proto-metabolism proposed by the Eschenmoser and Sutherland groups. Research from the Eschenmoser group suggested that interactions between HCN and aldehydes can catalyze the formation of diaminomaleodinitrile (DAMN). Iterations of this cycle would generate multiple intermediate metabolites and key biomolecular precursors through functional group transformations by hydrolytic and redox processes. To expand upon this finding, the Sutherland group experimentally assessed the assembly of biomolecular building blocks from prebiotic intermediates and one-carbon feedstocks. They synthesized precursors of ribonucleotides, amino acids and lipids from the reactants of hydrogen cyanide, acetylene, acrylonitrile (product of cyanide and acetylene), and dihydroxyacetone (stable triose isomer of glyceraldehyde and phosphate). These reactions are driven by UV light and use hydrogen sulfide (H2S) as the primary reductant in these reactions. As each of these synthesis reactions was tested independently and some reactions require periodic input of additional reactants, these biomolecular precursors were not strictly generated through a one-pot synthesis expected of early Earth environments. In the same work, these authors argue that flow chemistry or the movement of reactants through water could generate the conditions favorable for the synthesis of these molecules.
During Bush's second term, a controversy arose over the Justice Department's midterm dismissal of seven United States Attorneys. The White House maintained that they were fired for poor performance. Attorney General Alberto Gonzales later resigned over the issue, along with other senior members of the Justice Department. The House Judiciary Committee issued subpoenas for advisers Harriet Miers and Josh Bolten to testify regarding this matter, but Bush directed Miers and Bolten not to comply with those subpoenas, invoking his right of executive privilege. Bush maintained that all his advisers were covered under a broad executive privilege protection to receive candid advice. The Justice Department determined that the President's order was legal. Although congressional investigations focused on whether the Justice Department and the White House were using the U.S. Attorney positions for political advantage, no official findings have been released. On March 10, 2008, the Congress filed a federal lawsuit to enforce their issued subpoenas. On July 31, 2008, a United States district court judge ruled that Bush's top advisers were not immune from congressional subpoenas. In all, twelve Justice Department officials resigned rather than testify under oath before Congress. They included Attorney General Alberto Gonzales and his chief of staff Kyle Sampson, Gonzales' liaison to the White House Monica Goodling, aide to the president Karl Rove and his senior aide Sara Taylor.
=== Advantage === Komagataella is able to grow on simple, inexpensive medium, with high growth rate. Komagataella can grow in either shake flasks or a fermenter, which makes it suitable for both small- and large-scale production. Komagataella has two alcohol oxidase genes, Aox1 and Aox2, which include strongly inducible promoters. These two genes allow Komagataella to use methanol as a carbon and energy source. The AOX promoters are induced by methanol, and repressed by glucose. Usually, the gene for the desired protein is introduced under the control of the Aox1 promoter, which means that protein production can be induced by the addition of methanol on medium. After several researches, scientists found that the promoter derived from AOX1 gene in Komagataella is extremely suitable to control the expression of foreign genes, which had been transformed into the Komagataella genome, producing heterologous proteins. With a key trait, Komagataella can grow with extremely high cell density on the culture. This feature is compatible with heterologous protein expression, giving higher yields of production. Komagataella has a well-developed secretory pathway involving the Endoplasmic reticulum and a stacked Golgi apparatus, which is more similar to those of higher eukaryotes to that of Saccharomyces cerevisiae. This enables the efficient folding and post-translational modification of heterologous proteins, including the formation of disulfide bonds and glycosylation.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.